HuATN-658

HuATN-658 (MNPR-101) is a humanized monoclonal antibody inhibitor targeting urokinase-type plasminogen activator receptor (uPAR) . huATN-658 blocks the interaction between uPAR and integrins, inhibiting the proliferation, invasion and migration of tumor cells. huATN-658 is promising for research of breast cancer (especially triple-negative breast cancer) [1][2].

12352203

Integrin

Cytoskeleton

Cancer-Kinase/protease

Cancer

99.67

[huATN658]

(146.34 kDa)

[1]Mahmood N, et al. uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions. Bone Res. 2020 Apr 17;8:18.|[2]Nair R, et al. Preclinical Evaluation of Anti-uPAR Antibody as a Radiolabeled PET Imaging Candidate in Solid Tumors[J]. 2024.

Dry Ice

Store at -80°C for 2 years

http://file.medchemexpress.com/batch_PDF/HY-P990552A/huATN-658-SDS-MedChemExpress.pdf

Inhibitory Antibodies

No Development Reported